Show simple item record

dc.contributor.authorKärkkäinen Miia
dc.contributor.authorKettunen Hannu-Pekka
dc.contributor.authorNurmi Hanna
dc.contributor.authorSelander Tuomas
dc.contributor.authorPurokivi Minna
dc.contributor.authorKaarteenaho Riitta
dc.date.accessioned2018-02-08T13:02:56Z
dc.date.available2018-02-08T13:02:56Z
dc.date.issued2017
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/6004
dc.description.abstractBackground Cigarette smoking has been associated with the risk of idiopathic pulmonary fibrosis (IPF). Certain comorbidities have been associated with reduced survival although some studies have indicated that current smokers have a longer survival than ex-smokers. Comorbidities in relation to smoking history have not been previously analyzed. Methods Retrospective data was collected and patients were categorized according to gender and smoking habits. Comorbidities and medications were collected. Predictive values for mortality were identified by COX proportional hazard analyses. Results We examined 45 non-smokers (53.3% female), 66 ex-smokers (9.1% female) and 17 current smokers (17.6% female) with IPF. Current smokers were younger at baseline (58.1 ± 8.74 years) compared to non-smokers (71.4 ± 8.74, p < 0.001) and ex-smokers (72.5 ±7.95, p <0.001). Median survival of non-smokers and current smokers was longer (55.0 and 52.0 months, respectively) than that of ex-smokers (36.0 months) (p=0.028 and 0.034, respectively). In age and severity adjusted analyses, smoking was not related to survival. Cardiovascular diseases (CVD) (72.7 %) were the most common comorbidities, current smokers had more chronic obstructive pulmonary disease (COPD) and lung cancer compared to ex-smokers (p<0.001). CVD, COPD and use of insulin were related to poorer survival in adjusted analyses. Conclusions Smoking seems to influence the course of disease in IPF since current smokers developed the disease at a younger age in comparison to non-smokers and ex-smokers. No significant differences in the major comorbidities were detected between IPF patients with different smoking histories. The mechanism through which smoking influences IPF progression requires further investigation.en
dc.language.isoENen
dc.publisherSpringer Natureen
dc.relation.ispartofseriesRESPIRATORY RESEARCHen
dc.relation.urihttp://dx.doi.org/10.1186/s12931-017-0642-6en
dc.rightsCC BY http://creativecommons.org/licenses/by/4.0/en
dc.subjectIdiopathic pulmonary fibrosisen
dc.subjectsmokingen
dc.subjectgendercoen
dc.subjectmorbidityen
dc.titleEffect of smoking and comorbidities on survival in idiopathic pulmonary fibrosisen
dc.description.versionpublished versionen
dc.contributor.departmentSchool of Medicine / Clinical Medicineen
uef.solecris.id49307509en
dc.type.publicationinfo:eu-repo/semantics/articleen
dc.rights.accessrights© Authorsen
dc.relation.doi10.1186/s12931-017-0642-6en
dc.description.reviewstatuspeerRevieweden
dc.relation.articlenumber160en
dc.relation.issn1465-9921en
dc.relation.issue1en
dc.relation.volume18en
dc.rights.accesslevelopenAccessen
dc.type.okmA1en
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
uef.solecris.openaccessOpen access -julkaisukanavassa ilmestynyt julkaisu


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record